Perfusion process combining low temperature and valeric acid for enhanced recombinant factor VIII production.

Coronel J, Heinrich C, Klausing S, Noll T, Figueredo-Cardero A, Castilho LR (2019)
Biotechnology progress.

Zeitschriftenaufsatz | E-Veröff. vor dem Druck| Englisch
 
Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Autor*in
Coronel, Juliana; Heinrich, Christoph; Klausing, Sandra; Noll, ThomasUniBi ; Figueredo-Cardero, Alvio; Castilho, Leda R
Abstract / Bemerkung
Perfusion operation mode remains the preferred platform for production of labile biopharmaceuticals (e.g., blood factors) and is also being increasingly adopted for production of stable products (e.g., monoclonal antibodies). Regardless of the product, process development typically aims at maximizing production capacity. In this work, we investigated the impact of perfusion cultivation conditions on process productivity for production of human factor VIII (FVIII). Recombinant CHO cells were cultivated in bioreactors coupled to inclined settlers and the effects of reducing the temperature to 31°C with or without valeric acid (VA) supplementation were evaluated. Increases in cell specific productivity (qp ) up to 2.4-fold (FVIII concentration) and up to 3.0-fold (FVIII biological activity) were obtained at 31°C with VA compared to the control at 37°C. Biological activity is the most important quality attribute for FVIII and was positively affected by mild hypothermia in combination with the chemical inducer. The low temperature conditions resulted in enhanced product transcript levels, suggesting that the higher qp is related to the increased mRNA levels. Furthermore, a high-producer subclone was evaluated under the perfusion conditions optimized for the parental clone (31°C with VA), yielding increases in qp of 6-fold and 15-fold compared to the parental clone cultivated under the same condition and at 37°C, respectively. The proposed perfusion strategy enables increased product formation without increasing production costs, being potentially applicable to perfusion production of other CHO-derived biopharmaceuticals. To the best of our knowledge, this is the first report showing the benefits of perfusion combining mild hypothermia with VA supplementation. This article is protected by copyright. All rights reserved. © 2019 American Institute of Chemical Engineers.
Erscheinungsjahr
2019
Zeitschriftentitel
Biotechnology progress
ISSN
1520-6033
Page URI
https://pub.uni-bielefeld.de/record/2938369

Zitieren

Coronel J, Heinrich C, Klausing S, Noll T, Figueredo-Cardero A, Castilho LR. Perfusion process combining low temperature and valeric acid for enhanced recombinant factor VIII production. Biotechnology progress. 2019.
Coronel, J., Heinrich, C., Klausing, S., Noll, T., Figueredo-Cardero, A., & Castilho, L. R. (2019). Perfusion process combining low temperature and valeric acid for enhanced recombinant factor VIII production. Biotechnology progress. doi:10.1002/btpr.2915
Coronel, J., Heinrich, C., Klausing, S., Noll, T., Figueredo-Cardero, A., and Castilho, L. R. (2019). Perfusion process combining low temperature and valeric acid for enhanced recombinant factor VIII production. Biotechnology progress.
Coronel, J., et al., 2019. Perfusion process combining low temperature and valeric acid for enhanced recombinant factor VIII production. Biotechnology progress.
J. Coronel, et al., “Perfusion process combining low temperature and valeric acid for enhanced recombinant factor VIII production.”, Biotechnology progress, 2019.
Coronel, J., Heinrich, C., Klausing, S., Noll, T., Figueredo-Cardero, A., Castilho, L.R.: Perfusion process combining low temperature and valeric acid for enhanced recombinant factor VIII production. Biotechnology progress. (2019).
Coronel, Juliana, Heinrich, Christoph, Klausing, Sandra, Noll, Thomas, Figueredo-Cardero, Alvio, and Castilho, Leda R. “Perfusion process combining low temperature and valeric acid for enhanced recombinant factor VIII production.”. Biotechnology progress (2019).

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 31587517
PubMed | Europe PMC

Suchen in

Google Scholar